Home-Based Up-Dosing in Build-Up Phase of Oral Immunotherapy of Egg Allergy Is Safe and Feasible in Real-World Practice
Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the...
Saved in:
Published in | Allergy, asthma & immunology research Vol. 13; no. 5; pp. 791 - 798 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Seoul
Korean Academy of Asthma, Allergy and Clinical Immunology
01.09.2021
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 대한천식알레르기학회 |
Subjects | |
Online Access | Get full text |
ISSN | 2092-7355 2092-7363 |
DOI | 10.4168/aair.2021.13.5.791 |
Cover
Abstract | Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. |
---|---|
AbstractList | Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period ( P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. KCI Citation Count: 1 Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. |
Author | Jung, Minyoung Kim, Jihyun Kim, Sukyung Lee, Bora Jeong, Hye-In Lee, Ji Young Ahn, Kangmo Kyung, Yechan Kim, Kevin Kim, Minji |
AuthorAffiliation | 6 Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea 1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4 Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea 5 Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea 7 School of Arts and Sciences, University of Richmond, Richmond, VA, USA 2 Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea 3 Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea |
AuthorAffiliation_xml | – name: 6 Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea – name: 3 Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea – name: 7 School of Arts and Sciences, University of Richmond, Richmond, VA, USA – name: 2 Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea – name: 5 Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea – name: 1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – name: 4 Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea |
Author_xml | – sequence: 1 givenname: Hye-In orcidid: 0000-0001-8843-0651 surname: Jeong fullname: Jeong, Hye-In organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea – sequence: 2 givenname: Bora orcidid: 0000-0002-7718-1159 surname: Lee fullname: Lee, Bora organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea – sequence: 3 givenname: Sukyung orcidid: 0000-0002-3204-1398 surname: Kim fullname: Kim, Sukyung organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea – sequence: 4 givenname: Yechan orcidid: 0000-0002-4982-863X surname: Kyung fullname: Kyung, Yechan organization: Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea – sequence: 5 givenname: Minyoung orcidid: 0000-0003-2851-9480 surname: Jung fullname: Jung, Minyoung organization: Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea – sequence: 6 givenname: Minji orcidid: 0000-0001-5588-5414 surname: Kim fullname: Kim, Minji organization: Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea – sequence: 7 givenname: Ji Young orcidid: 0000-0002-2260-9939 surname: Lee fullname: Lee, Ji Young organization: Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea – sequence: 8 givenname: Kevin orcidid: 0000-0002-0220-1848 surname: Kim fullname: Kim, Kevin organization: School of Arts and Sciences, University of Richmond, Richmond, VA, USA – sequence: 9 givenname: Kangmo orcidid: 0000-0001-7751-9829 surname: Ahn fullname: Ahn, Kangmo organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea – sequence: 10 givenname: Jihyun orcidid: 0000-0001-8493-2881 surname: Kim fullname: Kim, Jihyun organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea |
BackLink | https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002751768$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kkFP3DAQhaOKqlDKH-jJUi_tIdvYsZ34UmmhUFZCAlFWPVqzyWTX4NiLnbTaf1-HRUjlUF9seb73NGO_99mB8w6z7CMtZpzK-iuACTNWMDqj5UzMKkXfZEesUCyvSlkevJyFOMxOYrwv0iop55K_yw5LzmvJJDvK_lz6HvNTiNiS5Tb_7qNxa2IcOR2NbfPlltxsUpH4jlwHsGTR96PzwwYDbHfT7fl6TebWYljvyCKSn9AhAdeSC4RoVhYnr1sEm__ywbbkJkAzmAY_ZG87sBFPnvfjbHlxfnd2mV9d_1icza_yhnM65I1iVckZq7qi45VoVwi0Q1CSYV0qKiUILCUFBjUViikAUTRYVKrtWtHWWB5nX_a-LnT6oTHag3na114_BD2_vVtoVYsqaRP7bc9ux1WPbYNuSCPrbTA9hN2T8t-KM5vk81vXnCrJ62Tw-dkg-McR46B7Exu0Fhz6MWompJK0Sr-Q0E-v0Hs_BpeeIlFVGphXNU0U21NN8DEG7F6aoYWeYqCnGOgpBpqWWugUgySqX4kaM8Bg_NS0sf-T_gWaP7fe |
CitedBy_id | crossref_primary_10_1007_s11882_024_01191_5 crossref_primary_10_1111_cea_70013 crossref_primary_10_2500_aap_2024_45_240001 crossref_primary_10_1016_j_mcna_2023_08_011 crossref_primary_10_1111_pai_14216 crossref_primary_10_1111_pai_14003 crossref_primary_10_3345_cep_2023_01123 crossref_primary_10_1016_j_pop_2022_11_006 crossref_primary_10_3345_cep_2023_00234 crossref_primary_10_2174_1389203723666220603155320 crossref_primary_10_4168_aard_2023_11_2_93 crossref_primary_10_1016_j_jaip_2024_09_025 |
Cites_doi | 10.1016/j.jaci.2005.12.1303 10.1111/j.1399-3038.2012.01349.x 10.1016/j.jaci.2018.08.041 10.1016/j.jaci.2010.11.044 10.4168/aair.2013.5.2.96 10.1016/j.jaci.2017.11.003 10.1016/j.jaip.2015.01.017 10.1016/j.jaip.2017.09.016 10.1016/j.jaci.2020.05.040 10.1016/j.jaci.2010.10.008 10.1111/pai.12974 10.4168/aard.2020.8.3.161 10.1111/ped.13210 10.4168/aair.2019.11.3.433 10.2500/ar.2017.8.0211 10.1056/NEJMoa1200435 10.4168/aair.2020.12.3.496 10.1016/j.jaci.2015.12.1316 10.4168/aair.2014.6.2.131 10.1542/peds.2011-0204 10.1016/j.anai.2016.11.023 |
ContentType | Journal Article |
Copyright | Copyright Korean Academy of Asthma, Allergy and Clinical Immunology Sep 2021 Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease. Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease |
Copyright_xml | – notice: Copyright Korean Academy of Asthma, Allergy and Clinical Immunology Sep 2021 – notice: Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease. – notice: Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease |
DBID | AAYXX CITATION 7T5 7U7 C1K H94 7X8 5PM ACYCR |
DOI | 10.4168/aair.2021.13.5.791 |
DatabaseName | CrossRef Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2092-7363 |
EndPage | 798 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9857929 PMC8419648 10_4168_aair_2021_13_5_791 |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 5-W 53G 8JR 8XY 9ZL AAKDD AAYXX ACPRK ADBBV ADRAZ AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION C~G DIK DYU E3Z EF. F5P GX1 HYE KQ8 M48 O5R O5S OK1 PGMZT RPM 7T5 7U7 C1K H94 7X8 5PM ACYCR M~E OZF |
ID | FETCH-LOGICAL-c441t-c92734227f0f475dbea1fea962e839166a5e361a2a815929aa50ce079dfd5d8e3 |
IEDL.DBID | M48 |
ISSN | 2092-7355 |
IngestDate | Tue Nov 21 21:16:37 EST 2023 Thu Aug 21 18:31:05 EDT 2025 Fri Jul 11 02:53:09 EDT 2025 Mon Jun 30 12:08:19 EDT 2025 Thu Apr 24 23:05:05 EDT 2025 Fri Jul 04 01:06:57 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | https://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c441t-c92734227f0f475dbea1fea962e839166a5e361a2a815929aa50ce079dfd5d8e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-8493-2881 0000-0003-2851-9480 0000-0001-8843-0651 0000-0002-3204-1398 0000-0002-7718-1159 0000-0002-4982-863X 0000-0002-2260-9939 0000-0002-0220-1848 0000-0001-5588-5414 0000-0001-7751-9829 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4168/aair.2021.13.5.791 |
PMID | 34486262 |
PQID | 2572274781 |
PQPubID | 2048270 |
PageCount | 8 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9857929 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8419648 proquest_miscellaneous_2569617144 proquest_journals_2572274781 crossref_primary_10_4168_aair_2021_13_5_791 crossref_citationtrail_10_4168_aair_2021_13_5_791 |
PublicationCentury | 2000 |
PublicationDate | 2021-09-01 |
PublicationDateYYYYMMDD | 2021-09-01 |
PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Seoul |
PublicationPlace_xml | – name: Seoul |
PublicationTitle | Allergy, asthma & immunology research |
PublicationYear | 2021 |
Publisher | Korean Academy of Asthma, Allergy and Clinical Immunology The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 대한천식알레르기학회 |
Publisher_xml | – name: Korean Academy of Asthma, Allergy and Clinical Immunology – name: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease – name: 대한천식알레르기학회 |
References | Sicherer (10.4168/aair.2021.13.5.791_ref2) 2011; 127 Shin (10.4168/aair.2021.13.5.791_ref20) 2013; 5 Horino (10.4168/aair.2021.13.5.791_ref21) 2019; 11 Gupta (10.4168/aair.2021.13.5.791_ref1) 2011; 128 Sampson (10.4168/aair.2021.13.5.791_ref9) 2006; 117 Burks (10.4168/aair.2021.13.5.791_ref6) 2012; 367 Akashi (10.4168/aair.2021.13.5.791_ref17) 2017; 59 Nowak-Węgrzyn (10.4168/aair.2021.13.5.791_ref7) 2019; 143 Boyce (10.4168/aair.2021.13.5.791_ref4) 2010; 126 Kim (10.4168/aair.2021.13.5.791_ref14) 2020; 8 Bird (10.4168/aair.2021.13.5.791_ref8) 2018; 6 Meglio (10.4168/aair.2021.13.5.791_ref16) 2017; 8 Park (10.4168/aair.2021.13.5.791_ref3) 2014; 6 Lee (10.4168/aair.2021.13.5.791_ref10) 2020; 12 Caminiti (10.4168/aair.2021.13.5.791_ref15) 2015; 3 Martín-Muñoz (10.4168/aair.2021.13.5.791_ref11) 2019; 30 Pérez-Rangel (10.4168/aair.2021.13.5.791_ref12) 2017; 118 Dello Iacono (10.4168/aair.2021.13.5.791_ref13) 2013; 24 Kim (10.4168/aair.2021.13.5.791_ref19) 2020; 146 Sicherer (10.4168/aair.2021.13.5.791_ref5) 2018; 141 Jones (10.4168/aair.2021.13.5.791_ref18) 2016; 137 |
References_xml | – volume: 117 start-page: 391 year: 2006 ident: 10.4168/aair.2021.13.5.791_ref9 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.12.1303 – volume: 24 start-page: 66 year: 2013 ident: 10.4168/aair.2021.13.5.791_ref13 publication-title: Pediatr Allergy Immunol doi: 10.1111/j.1399-3038.2012.01349.x – volume: 143 start-page: 651 year: 2019 ident: 10.4168/aair.2021.13.5.791_ref7 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.08.041 – volume: 127 start-page: 594 year: 2011 ident: 10.4168/aair.2021.13.5.791_ref2 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.11.044 – volume: 5 start-page: 96 year: 2013 ident: 10.4168/aair.2021.13.5.791_ref20 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2013.5.2.96 – volume: 141 start-page: 41 year: 2018 ident: 10.4168/aair.2021.13.5.791_ref5 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.11.003 – volume: 3 start-page: 532 year: 2015 ident: 10.4168/aair.2021.13.5.791_ref15 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2015.01.017 – volume: 6 start-page: 476 year: 2018 ident: 10.4168/aair.2021.13.5.791_ref8 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2017.09.016 – volume: 146 start-page: 851 year: 2020 ident: 10.4168/aair.2021.13.5.791_ref19 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.05.040 – volume: 126 start-page: 1105 year: 2010 ident: 10.4168/aair.2021.13.5.791_ref4 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.10.008 – volume: 30 start-page: 81 year: 2019 ident: 10.4168/aair.2021.13.5.791_ref11 publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.12974 – volume: 8 start-page: 161 year: 2020 ident: 10.4168/aair.2021.13.5.791_ref14 publication-title: Allergy Asthma Respir Dis doi: 10.4168/aard.2020.8.3.161 – volume: 59 start-page: 534 year: 2017 ident: 10.4168/aair.2021.13.5.791_ref17 publication-title: Pediatr Int doi: 10.1111/ped.13210 – volume: 11 start-page: 433 year: 2019 ident: 10.4168/aair.2021.13.5.791_ref21 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2019.11.3.433 – volume: 8 start-page: 157 year: 2017 ident: 10.4168/aair.2021.13.5.791_ref16 publication-title: Allergy Rhinol (Providence) doi: 10.2500/ar.2017.8.0211 – volume: 367 start-page: 233 year: 2012 ident: 10.4168/aair.2021.13.5.791_ref6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200435 – volume: 12 start-page: 496 year: 2020 ident: 10.4168/aair.2021.13.5.791_ref10 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2020.12.3.496 – volume: 137 start-page: 1117 year: 2016 ident: 10.4168/aair.2021.13.5.791_ref18 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.12.1316 – volume: 6 start-page: 131 year: 2014 ident: 10.4168/aair.2021.13.5.791_ref3 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2014.6.2.131 – volume: 128 start-page: e9 year: 2011 ident: 10.4168/aair.2021.13.5.791_ref1 publication-title: Pediatrics doi: 10.1542/peds.2011-0204 – volume: 118 start-page: 356 year: 2017 ident: 10.4168/aair.2021.13.5.791_ref12 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2016.11.023 |
SSID | ssj0000314464 |
Score | 2.3082829 |
Snippet | Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase... |
SourceID | nrf pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 791 |
SubjectTerms | Accumulation Allergic reactions Allergies Anaphylaxis Brief Communication Children Desensitization Dosage Eggs Feasibility Immunotherapy Patients Safety Side effects 내과학 |
Title | Home-Based Up-Dosing in Build-Up Phase of Oral Immunotherapy of Egg Allergy Is Safe and Feasible in Real-World Practice |
URI | https://www.proquest.com/docview/2572274781 https://www.proquest.com/docview/2569617144 https://pubmed.ncbi.nlm.nih.gov/PMC8419648 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002751768 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Allergy, 2021, Asthma & Immunology Research, 13(5), , pp.791-798 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fT9swELYYk6a9TBtsWhlDZtobcpbEdmI_TbCB6CQGYovEnizXsUtFlXSlCPrf7y5NKyIB0p6ixD8S-7N938W-O0I-K865jF0OCLjAhLaSDVTCmQIqkvrQeN3C0xY_s-NC_LiQF2tkGe6o7cDrB1U7jCdVTMfR3d_5V5jwwF8joBPqi7Uj9OyZJlHCIxnlaMz-HCRThsrYSUv3m5WZo_aDG81prIFYgqxd2NE8Uk1HVj2rpqFDQ7uHKO9JpaPX5FVLJ-n-Av83ZM1XG-TFSbthvkluMQw6OwBRVdJiwr7X-GuAjip6gOGwWTGhZ5eQSOtAT6F62kdzkdYoa45PD4dDuo_mgsM57V_TXzZ4aquSAnWEyTT2WNc5kE3WnMqhZ63R1VtSHB3-_nbM2lgLzAEhmjGn0c9NmuYhDiKX5cDbJHirATCFtrmZlZ5niU2tAgKUamsBYR_nugylLJXn78h6VVf-PaFQIIMHZSy8Be1NaZEPtBOBC5s5l-geSZa9alzriBzjYYwNKCSIhEEkDCJhEm6kASR6ZG9VZrJww_Fk7k8AlrlyI4Pes_E6rM3V1ICO0DdayRxa0CPbSyzNctgZWMBS1NMV1LG7SoYZh9sotvL1DebJdIZx40WP5J0xsPo0fGs3pRpdNr67lUAPaGrrv9rzgbzE-8XRtm2yPpve-I_AhWaDHdAC_hQ7zTD_B1GABKc |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Home-Based+Up-Dosing+in+Build-Up+Phase+of+Oral+Immunotherapy+of+Egg+Allergy+Is+Safe+and+Feasible+in+Real-World+Practice&rft.jtitle=Allergy%2C+asthma+%26+immunology+research&rft.au=Jeong%2C+Hye-In&rft.au=Lee%2C+Bora&rft.au=Kim%2C+Sukyung&rft.au=Kyung%2C+Yechan&rft.date=2021-09-01&rft.issn=2092-7355&rft.eissn=2092-7363&rft.volume=13&rft.issue=5&rft.spage=791&rft_id=info:doi/10.4168%2Faair.2021.13.5.791&rft.externalDBID=n%2Fa&rft.externalDocID=10_4168_aair_2021_13_5_791 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-7355&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-7355&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-7355&client=summon |